Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

COG5 Gene Glycosylation Disorder Type 2I Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Clinical Certainty: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM – 11 PM).

Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation from a Consultant Medical Genetics.

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced genetic test employs Next Generation Sequencing (NGS) to analyze the entire coding region of the COG5 gene, detecting pathogenic variants linked to the rare autosomal recessive metabolic disorder Congenital Disorder of Glycosylation type IIi (CDG‑2I). Early molecular diagnosis enables targeted metabolic management and informed genetic counselling for pediatric and adult patients with unexplained developmental delay, liver dysfunction, coagulopathy, or neurological regression.

FeatureOur NGS TestClosest Alternative
MethodologyFull-gene NGS with CNV analysisSingle‑exon Sanger sequencing
Diagnostic Sensitivity99.9%~85% (misses large deletions)
Turnaround Time3‑4 Weeks4‑8 Weeks (fragmented)
ISO AccreditationISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)Not always certified
Home CollectionVIP Cold‑Chain PhlebotomyClinic‑only

Physician Insight & Safety Protocols

"As a consultant medical geneticist, I recognise that families often face prolonged uncertainty when awaiting genetic diagnoses. This NGS-based test offers comprehensive coverage of the COG5 gene, but results must always be interpreted in the context of full clinical history and family pedigree. A detected variant alone should never prompt immediate treatment changes without expert metabolic review."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Safety Advisory

Do not discontinue any prescribed medication or metabolic supplement without consulting your treating physician. Sudden cessation can precipitate metabolic crisis in CDG patients.

Test Exclusion Criteria & Emergency Red Flags

  • Not for acute emergencies: This test is elective and will not provide results in time for acute metabolic decompensation.
  • Individuals with active severe infection or recent blood transfusion (within 2 weeks) should defer sample collection until clinically stable, as these may affect DNA quality.
  • Patients currently in a metabolic crisis (e.g., intractable seizures, acute liver failure) must be stabilized before testing.

Seek Immediate Medical Attention if you experience sudden lethargy, vomiting, hemorrhage, or loss of consciousness. Visit the nearest emergency department.

Patient FAQ & Clinical Guidance

1. What is the turnaround time for the COG5 NGS test?

Direct Answer: Reports are typically issued within 3 to 4 weeks from sample receipt at our ISO‑accredited facility.

2. Who should consider undergoing this genetic analysis?

Direct Answer: Anyone with clinical signs suggestive of CDG type IIi — such as developmental delay, coagulation defects, or unexplained liver dysfunction — and individuals with a confirmed family history of COG5‑related disease.

3. What sample types are accepted and how is the collection done?

Direct Answer: We accept whole blood (EDTA), extracted DNA, or a drop of blood on an FTA card; all options are eligible for VIP home collection with temperature‑controlled cold‑chain transport.

UAE Regulatory & Data Privacy Adherence

This test is performed at DNA Labs UAE, a DHA‑licensed facility (License No. 1143) operating in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed under strict confidentiality protocols. Your privacy and data security are paramount.

Clinical & Logistical Metadata

Test Name COG5 Gene Glycosylation Disorder Type 2I Genetic Test
Price (AED) 2,800
Turnaround Time 3 – 4 weeks
Sample Type / Matrix Peripheral whole blood (EDTA), extracted DNA, or dried blood spot (FTA card)
Methodology Used Next Generation Sequencing (full‑gene NGS with CNV analysis)
ICD-10-CM Code E77.8 (Other disorders of glycoprotein metabolism)
LOINC Code 83240-0 (DNA sequencing)
DHA Facility License & Lab Address DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians